Bausch Health Companies (BHC) PT Lowered to $14 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bausch Health Announces Third-Quarter 2022 Results
November 3, 2022 7:01 AM EDTRevenues of $2.046 billion, down 3% reported, up 2% organic basisThird quarter sales improved sequentially, notably Salix, International, and SoltaSuccessful debt exchange offer reduces debt by $2.5 billionCompany updates full year guidance
LAVAL, QC / ACCESSWIRE / November 3, 2022 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2022 financial results.
"We are encouraged with the top line... More
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
November 1, 2022 8:01 AM EDTNine Poster Presentations Include New Analyses of SILIQ and JUBLIA
LAVAL, QC / ACCESSWIRE / November 1, 2022 / - Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev. The presentations will feature new data around JUBLIA (efinaconazole) Topical Solution, 10%, and SILIQ (brodalumab) Injection, 210 mg/1.5 mL. There will also be six encore presentations, including analyses of DUOBRII (halobetasol propionate and... More
